

Helen K Reddel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5599999/publications.pdf>

Version: 2024-02-01

220
papers

14,256
citations

28736

57
h-index

25983

112
g-index

224
all docs

224
docs citations

224
times ranked

11568
citing authors

#	ARTICLE	IF	CITATIONS
1	A Practical Guide to Implementing SMART in Asthma Management. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, S31-S38.	2.0	34
2	Global Initiative for Asthma Strategy 2021. Respiriology, 2022, 27, 14-35.	1.3	31
3	Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. European Respiratory Journal, 2022, 59, 2102730.	3.1	218
4	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 17-35.	2.5	196
5	Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes. Archivos De Bronconeumología, 2022, 58, 35-51.	0.4	31
6	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, S1-S18.	2.0	66
7	Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study. BMJ Open, 2022, 12, e048537.	0.8	10
8	Asthma management in low and middle income countries: case for change. European Respiratory Journal, 2022, 60, 2103179.	3.1	45
9	Reply to: GINA 2021: Asthma in Pre-School Children and SABA-Only Treatment. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	0
10	Common conditions that mimic asthma. Medical Journal of Australia, 2022, 216, 337-340.	0.8	2
11	Insights from the AUSTRI study on reliever use before and after asthma exacerbations. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1916-1918.e2.	2.0	6
12	Novel Methods of Measuring Adherence Patterns Reveal Adherence Phenotypes with Distinct Asthma Outcomes. Annals of the American Thoracic Society, 2022, 19, 933-942.	1.5	4
13	The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study. Respiratory Medicine, 2022, 200, 106863.	1.3	8
14	Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study. Respiratory Medicine, 2022, 200, 106921.	1.3	14
15	Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetings. Internal Medicine Journal, 2021, 51, 169-180.	0.5	5
16	Effect of a single day of increased as-needed budesonide/formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respiratory Medicine, 2021, 9, 149-158.	5.2	46
17	Budesonide/formoterol reliever therapy in intermittent versus mild persistent asthma. European Respiratory Journal, 2021, 57, 2003064.	3.1	10
18	The management of mild asthma. European Respiratory Journal, 2021, 57, 2003051.	3.1	15

#	ARTICLE	IF	CITATIONS
19	Barriers to belonging: the need for relatedness amongst people living with severe asthma. <i>Journal of Asthma</i> , 2021, 58, 1-9.	0.9	9
20	Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. <i>Drug Safety</i> , 2021, 44, 467-478.	1.4	8
21	Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2715-2724.e5.	2.0	15
22	Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. <i>European Respiratory Journal</i> , 2021, 58, 2003927.	3.1	43
23	Reply: About the recommendation of the GINA strategy report on asthma step 1. <i>European Respiratory Journal</i> , 2021, 57, 2004226.	3.1	2
24	Improving lung health in low-income and middle-income countries: from challenges to solutions. <i>Lancet, The</i> , 2021, 397, 928-940.	6.3	176
25	Positioning As-needed Budesonide-Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2. <i>Annals of the American Thoracic Society</i> , 2021, 18, 2007-2017.	1.5	17
26	Prevalence and burden of breathlessness in Australian adults: The National Breathlessness Survey—a cross-sectional web-based population survey. <i>Respirology</i> , 2021, 26, 768-775.	1.3	27
27	Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2255-2261.	2.0	76
28	Dynamics of inhaled corticosteroid use are associated with asthma attacks. <i>Scientific Reports</i> , 2021, 11, 14715.	1.6	4
29	Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3069-3077.e6.	2.0	22
30	Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand. <i>Respirology</i> , 2021, 26, 1112-1130.	1.3	35
31	Reply to “As-needed budesonide-formoterol for adolescents with mild asthma: importance of lung function”. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4179-4180.	2.0	0
32	Validation of a diagnosis-agnostic symptom questionnaire for asthma and/or COPD. <i>ERJ Open Research</i> , 2021, 7, 00828-2020.	1.1	6
33	Breathlessness, Anxiety, Depression, and Function—The BAD-F Study: A Cross-Sectional and Population Prevalence Study in Adults. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 197-205.e2.	0.6	40
34	Are the 2019 Global Initiative for Asthma (GINA) strategy recommendations applicable to the Canadian context?. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 3-6.	0.2	3
35	Severe Asthma Toolkit: an online resource for multidisciplinary health professionals’ needs assessment, development process and user analytics with survey feedback. <i>BMJ Open</i> , 2020, 10, e032877.	0.8	7
36	What matters most to patients when choosing treatment for mild-to-moderate asthma? Results from a discrete choice experiment. <i>Thorax</i> , 2020, 75, 842-848.	2.7	11

#	ARTICLE	IF	CITATIONS
37	The burden of exacerbations in mild asthma: a systematic review. <i>ERJ Open Research</i> , 2020, 6, 00359-2019.	1.1	33
38	“It is like learning how to live all over again”™ A systematic review of people’s experiences of living with a chronic illness from a self-determination theory perspective. <i>Health Psychology and Behavioral Medicine</i> , 2020, 8, 270-291.	0.8	14
39	Patient preferences for asthma management: a qualitative study. <i>BMJ Open</i> , 2020, 10, e037491.	0.8	15
40	Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 671-680.	5.2	81
41	GINA fosters World Asthma Day 2020 to prevent asthma deaths. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 318, L998-L1000.	1.3	8
42	Mepolizumab effectiveness and identification of super-responders in severe asthma. <i>European Respiratory Journal</i> , 2020, 55, 1902420.	3.1	124
43	GINA recommendations in adults with symptomatic mild asthma and a smoking history. <i>European Respiratory Journal</i> , 2020, 55, 2000068.	3.1	2
44	Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial. <i>European Respiratory Journal</i> , 2020, 55, 1902073.	3.1	33
45	Updated Australian guidelines for mild asthma: what's changed and why?. <i>Australian Prescriber</i> , 2020, 43, 220-224.	0.5	2
46	General practitioners' views on the influence of cost on the prescribing of asthma preventer medicines: a qualitative study. <i>Australian Health Review</i> , 2019, 43, 246.	0.5	5
47	Monitoring Adherence to Inhaled Medications”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 693.	3.8	0
48	Difficult-to-treat and severe asthma in general practice: delivery and evaluation of an educational program. <i>BMC Family Practice</i> , 2019, 20, 99.	2.9	4
49	Cost-Related Underuse of Medicines for Asthma”Opportunities for Improving Adherence. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2298-2306.e12.	2.0	36
50	GINA 2019: a fundamental change in asthma management. <i>European Respiratory Journal</i> , 2019, 53, 1901046.	3.1	277
51	The Global Initiative for Asthma (GINA): 25...years later. <i>European Respiratory Journal</i> , 2019, 54, 1900598.	3.1	174
52	Living with severe asthma: the role of perceived competence and goal achievement. <i>Chronic Illness</i> , 2019, 17, 174239531988410.	0.6	3
53	Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. <i>Lancet</i> , 2019, 394, 919-928.	6.3	180
54	Defining severe obstructive lung disease in the biologic era: an endotype-based approach. <i>European Respiratory Journal</i> , 2019, 54, 1900108.	3.1	12

#	ARTICLE	IF	CITATIONS
55	Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1180-1186.	1.5	45
56	Prospective observational study in patients with obstructive lung disease: NOVELTY design. <i>ERJ Open Research</i> , 2019, 5, 00036-2018.	1.1	29
57	Controlled Trial of Budesonide+Formoterol as Needed for Mild Asthma. <i>New England Journal of Medicine</i> , 2019, 380, 2020-2030.	13.9	308
58	Home-based Forced Oscillation Technique Day-to-Day Variability in Pediatric Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1156-1160.	2.5	16
59	The impact of severe asthma on patients' autonomy: A qualitative study. <i>Health Expectations</i> , 2019, 22, 528-536.	1.1	18
60	"You've got to breathe, you know" asthma patients and carers' perceptions around purchase and use of asthma preventer medicines. <i>Australian and New Zealand Journal of Public Health</i> , 2019, 43, 207-213.	0.8	5
61	Integrated Adherence Monitoring for Inhaler Medications. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1045.	3.8	23
62	"Everybody's Got Asthma" When Misunderstanding and Public Opinion Become Obstacles to the Care of Patients with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2622-2623.	2.0	1
63	Response: The most fundamental change in asthma management in 30...years?. <i>European Respiratory Journal</i> , 2019, 54, 1901860.	3.1	2
64	Treatable traits can be identified in a severe asthma registry and predict future exacerbations. <i>Respirology</i> , 2019, 24, 37-47.	1.3	136
65	Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis. <i>Pharmacoeconomics</i> , 2019, 37, 227-238.	1.7	4
66	"I've said I wish I was dead, you'd be better off without me" A systematic review of people's experiences of living with severe asthma. <i>Journal of Asthma</i> , 2019, 56, 311-322.	0.9	33
67	Difficult-to-treat and severe asthma in adults: Towards a new treatment paradigm. <i>Australian Journal of General Practice</i> , 2019, 48, 188-192.	0.3	2
68	Evaluation of difficult-to-treat and severe asthma in adults. , 2019, , 265-284.		2
69	Characteristics by physician-assigned severity of asthma, asthma+COPD and COPD patients in the NOVELTY study. , 2019, , .		1
70	Working while unwell: Workplace impairment in people with severe asthma. <i>Clinical and Experimental Allergy</i> , 2018, 48, 650-662.	1.4	57
71	Emerging Concepts in Evidence-Based Asthma Management. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 082-90.	0.8	1
72	Asthma. <i>Lancet, The</i> , 2018, 391, 783-800.	6.3	1,105

#	ARTICLE	IF	CITATIONS
73	Exacerbations in Adults with Asthma: A Systematic Review and External Validation of Prediction Models. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1942-1952.e15.	2.0	49
74	“This illness diminishes me. What it does is like theft” A qualitative meta-synthesis of people's experiences of living with asthma. <i>Health Expectations</i> , 2018, 21, 23-40.	1.1	21
75	Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire data. <i>Journal of Pragmatic and Observational Research</i> , 2018, Volume 9, 29-42.	1.1	18
76	As-Needed Budesonide/Formoterol in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 379, 897-898.	13.9	11
77	Underdiagnosis and Overdiagnosis of Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1012-1020.	2.5	213
78	Inhaled Combined Budesonide/Formoterol as Needed in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 1865-1876.	13.9	453
79	As-Needed Budesonide/Formoterol versus Maintenance Budesonide in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 1877-1887.	13.9	368
80	Inhaler technique education and asthma control among patients hospitalized for asthma in Jordan. <i>Saudi Pharmaceutical Journal</i> , 2018, 26, 1127-1136.	1.2	14
81	Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. , 2018, , .		1
82	Clustering of adherence variability metrics and clinical outcomes in asthma. , 2018, , .		1
83	The cost of asthma medicines. <i>Australian Prescriber</i> , 2018, 41, 34-36.	0.5	11
84	Identification of treatable traits in a severe asthma registry: prevalence and exacerbation predictors. , 2018, , .		0
85	Barriers and outcomes of an evidence-based approach to diagnosis and management of chronic obstructive pulmonary disease (COPD) in Australia: a qualitative study. <i>Family Practice</i> , 2017, 34, cmw103.	0.8	11
86	The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given “as needed” in mild asthma: study protocols for two randomised controlled trials. <i>Trials</i> , 2017, 18, 12.	0.7	30
87	Reply: Complexity Analysis of Respiratory Dynamics. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 248-249.	2.5	0
88	Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. <i>Lancet</i> , The, 2017, 389, 157-166.	6.3	158
89	Severe asthma: Current management, targeted therapies and future directions” A roundtable report. <i>Respirology</i> , 2017, 22, 53-60.	1.3	50
90	American Thoracic Society/National Heart, Lung, and Blood Institute Asthma “Chronic Obstructive Pulmonary Disease Overlap Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 375-381.	2.5	86

#	ARTICLE	IF	CITATIONS
91	Patient-perceived acceptability and behaviour change benefits of inhaler reminders and adherence feedback: A qualitative study. <i>Respiratory Medicine</i> , 2017, 129, 39-45.	1.3	30
92	Effect of novel inhaler technique reminder labels on the retention of inhaler technique skills in asthma: a single-blind randomized controlled trial. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 9.	1.1	35
93	Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 449-455.	1.3	5
94	Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000217.	1.2	15
95	Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. <i>BMJ Open</i> , 2017, 7, e016688.	0.8	52
96	“œI have lost in every facet of my life” the hidden burden of severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1700765.	3.1	128
97	Severe and Difficult-to-Treat Asthma in Adults. <i>New England Journal of Medicine</i> , 2017, 377, 965-976.	13.9	357
98	Is higher population-level use of ICS/LABA combination associated with better asthma outcomes? Cross-sectional surveys of nationally representative populations in New Zealand and Australia. <i>Respirology</i> , 2017, 22, 1570-1578.	1.3	16
99	Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment. <i>BMC Pulmonary Medicine</i> , 2017, 17, 65.	0.8	6
100	Effect of smoking status on the efficacy of the SMART regimen in high risk asthma “ Reply. <i>Respirology</i> , 2016, 21, 968-969.	1.3	0
101	Effect of smoking status on the efficacy of the SMART regimen in high risk asthma. <i>Respirology</i> , 2016, 21, 858-866.	1.3	14
102	Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model. <i>Thorax</i> , 2016, 71, 838-846.	2.7	74
103	Associations between inhaler technique and asthma control among asthma patients using pressurised MDIs and DPIs. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 689-695.	0.6	21
104	Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. <i>Internal Medicine Journal</i> , 2016, 46, 1054-1062.	0.5	68
105	Systems Biology and Clinical Practice in Respiratory Medicine. The Twain Shall Meet. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1053-1061.	2.5	44
106	Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. <i>Clinical and Experimental Allergy</i> , 2016, 46, 1407-1415.	1.4	29
107	Early intervention for chronic obstructive pulmonary disease by practice nurse and GP teams: a cluster randomized trial. <i>Family Practice</i> , 2016, 33, 663-670.	0.8	80
108	Should the diagnosis of COPD be based on a single spirometry test?. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16059.	1.1	39

#	ARTICLE	IF	CITATIONS
109	Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma. <i>European Respiratory Journal</i> , 2016, 47, 981-984.	3.1	18
110	Absence of back to school peaks in human rhinovirus detections and respiratory symptoms in a cohort of children with asthma. <i>Journal of Medical Virology</i> , 2016, 88, 578-587.	2.5	11
111	General practitioner-delivered adherence counseling in asthma: feasibility and usefulness of skills, training and support tools. <i>Journal of Asthma</i> , 2016, 53, 311-320.	0.9	12
112	Inter-professional education unveiling significant association between asthma knowledge and inhaler technique. <i>Pharmacy Practice</i> , 2016, 14, 713.	0.8	10
113	Uncovering the reality of life with severe asthma. , 2016, , .		0
114	The GINA asthma strategy report: what's new for primary care?. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 15050.	1.1	61
115	Asthma control in Australia: a cross-sectional web-based survey in a nationally representative population. <i>Medical Journal of Australia</i> , 2015, 202, 492-496.	0.8	98
116	The revised 2014 GINA strategy report. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 1-7.	1.2	116
117	Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1457-1464.e4.	1.5	88
118	The reliability and utility of spirometry performed on people with asthma in community pharmacies. <i>Journal of Asthma</i> , 2015, 52, 913-919.	0.9	8
119	The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?. <i>Lancet Respiratory Medicine</i> , 2015, 3, 719-728.	5.2	142
120	Barriers and facilitators to patient recruitment to a cluster randomized controlled trial in primary care: lessons for future trials. <i>BMC Medical Research Methodology</i> , 2015, 15, 18.	1.4	49
121	Treatment of overlapping asthma-chronic obstructive pulmonary disease: Can guidelines contribute in an evidence-free zone?. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 546-552.	1.5	43
122	A summary of the new GINA strategy: a roadmap to asthma control. <i>European Respiratory Journal</i> , 2015, 46, 622-639.	3.1	636
123	Rhinoviruses significantly affect day-to-day respiratory symptoms of children with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 663-669.e12.	1.5	27
124	Identifying patients at risk for future exacerbations of asthma: Development of a prediction model. , 2015, , .		0
125	Quality Standards for Real-World Research. Focus on Observational Database Studies of Comparative Effectiveness. <i>Annals of the American Thoracic Society</i> , 2014, 11, S99-S104.	1.5	115
126	Self-management support and other alternatives to reduce the burden of asthma and chronic obstructive pulmonary disease. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 1396-1406.	0.6	13

#	ARTICLE	IF	CITATIONS
127	Eosinophilic Inflammation in Subjects with Mild-to-Moderate Asthma with and without Obesity: Disparity between Sputum and Biopsies. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1281-1284.	2.5	20
128	Inconclusive evidence about the efficacy of diverse strategies for intermittent versus daily inhaled corticosteroids for persistent asthma in adults and children. <i>Evidence-Based Medicine</i> , 2014, 19, e2-e2.	0.6	3
129	Inhaler reminders improve adherence with controller treatment in primary care patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1260-1268.e3.	1.5	198
130	Combination corticosteroid/ β_2 -agonist inhaler as reliever therapy: A solution for intermittent and mild asthma?. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 39-41.	1.5	55
131	Asthma and Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2014, 35, 143-156.	0.8	80
132	Inhaler Technique Training and Health-Care Professionals: Effective Long-Term Solution for a Current Problem. <i>Respiratory Care</i> , 2014, 59, 1716-1725.	0.8	51
133	Predictors of Severe Exacerbations, Poor Asthma Control, and β_2 -Agonist Overuse for Patients with Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 751-758.e1.	2.0	56
134	Checklists for Powder Inhaler Technique: A Review and Recommendations. <i>Respiratory Care</i> , 2014, 59, 1140-1154.	0.8	65
135	The Effect of Inhaled IFN- β on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 145-154.	2.5	231
136	Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. <i>BMJ</i> , The, 2014, 348, g3009-g3009.	3.0	50
137	Performance of a brief asthma control screening tool in community pharmacy: a cross-sectional and prospective longitudinal analysis. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2014, 23, 79-84.	2.5	10
138	World Asthma Day. GINA 2014: a global asthma strategy for a global problem. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 505-506.	0.6	25
139	The contribution of goal specificity to goal achievement in collaborative goal setting for the management of asthma. <i>Research in Social and Administrative Pharmacy</i> , 2013, 9, 918-929.	1.5	24
140	Clinical control of asthma associates with measures of airway inflammation. <i>Thorax</i> , 2013, 68, 19-24.	2.7	56
141	Adherence Monitoring and E-Health: How Clinicians and Researchers Can Use Technology to Promote Inhaler Adherence for Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 446-454.	2.0	99
142	Integrating real-life studies in the global therapeutic research framework. <i>Lancet Respiratory Medicine</i> , the, 2013, 1, e29-e30.	5.2	102
143	Inappropriate prescribing of inhaled corticosteroids: are they being prescribed for respiratory tract infections? A retrospective cohort study. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2013, 22, 201-208.	2.5	18
144	Feasibility and Effectiveness of an Evidence-Based Asthma Service in Australian Community Pharmacies: A Pragmatic Cluster Randomized Trial. <i>Journal of Asthma</i> , 2013, 50, 302-309.	0.9	87

#	ARTICLE	IF	CITATIONS
145	Metrics of salbutamol use as predictors of future adverse outcomes in asthma. <i>Clinical and Experimental Allergy</i> , 2013, 43, 1144-1151.	1.4	61
146	Authors'™ response. <i>Thorax</i> , 2013, 68, 295.2-296.	2.7	9
147	Impact of graphic format on perception of change in biological data: implications for health monitoring in conditions such as asthma. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2012, 21, 94-100.	2.5	5
148	Trends In The Prevalence Of Asthma In Australia. , 2012, , .		0
149	Treating According to Asthma Control. <i>Clinics in Chest Medicine</i> , 2012, 33, 505-517.	0.8	11
150	The Reliability and Patient Acceptability of the SmartTrack Device: A New Electronic Monitor and Reminder Device for Metered Dose Inhalers. <i>Journal of Asthma</i> , 2012, 49, 657-662.	0.9	55
151	Control charts demonstrated limited utility for the monitoring of lung function in asthma. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 53-61.	2.4	5
152	Experiences of community pharmacists involved in the delivery of a specialist asthma service in Australia. <i>BMC Health Services Research</i> , 2012, 12, 164.	0.9	43
153	A pragmatic cluster randomized controlled trial of early intervention for chronic obstructive pulmonary disease by practice nurse-general practitioner teams: Study Protocol. <i>Implementation Science</i> , 2012, 7, 83.	2.5	24
154	Identifying patient-specific beliefs and behaviours for conversations about adherence in asthma. <i>Internal Medicine Journal</i> , 2012, 42, e136-44.	0.5	72
155	Rational prescribing for ongoing management of asthma in adults. <i>Australian Prescriber</i> , 2012, 35, 43-46.	0.5	4
156	Rational prescribing for asthma in adults " written asthma action plans. <i>Australian Prescriber</i> , 2012, 35, 78-81.	0.5	5
157	Predicting future risk of asthma exacerbations using individual conditional probabilities. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1494-1502.e3.	1.5	59
158	Using the Community Pharmacy to Identify Patients at Risk of Poor Asthma Control and Factors which Contribute to this Poor Control. <i>Journal of Asthma</i> , 2011, 48, 914-922.	0.9	59
159	Horizontally Compressed Charts Aid Visual Interpretation Of Biological Data. , 2011, , .		0
160	Action needed on asthma plans. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2011, 20, 116-117.	2.5	2
161	Year-in-review 2010: Asthma, COPD, cystic fibrosis and airway biology. <i>Respirology</i> , 2011, 16, 540-552.	1.3	5
162	Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. <i>Respiratory Research</i> , 2011, 12, 38.	1.4	58

#	ARTICLE	IF	CITATIONS
163	User Error With Diskus and Turbuhaler by Asthma Patients and Pharmacists in Jordan and Australia. <i>Respiratory Care</i> , 2011, 56, 1916-1923.	0.8	54
164	Assessing The Reliability And Validity Of The Smarttrack: An Electronic Adherence Monitor For Pressurized Metered Dose Inhalers (PMDI). , 2011, , .		0
165	Effect of different asthma treatments on risk of cold-related exacerbations. <i>European Respiratory Journal</i> , 2011, 38, 584-593.	3.1	35
166	Indices of bronchial reactivity and sensitivity. <i>Thorax</i> , 2011, 66, 265-266.	2.7	4
167	Single maintenance and reliever therapy (SMART) of asthma. <i>Thorax</i> , 2011, 66, 86-87.	2.7	5
168	Pharmacists' perceptions of their role in asthma management and barriers to the provision of asthma services. <i>International Journal of Pharmacy Practice</i> , 2010, 18, 209-216.	0.3	45
169	Asthma: Time to confront some inconvenient truths. <i>Respirology</i> , 2010, 15, 194-201.	1.3	20
170	Yearâ€inâ€review 2009: Asthma, COPD and airway biology. <i>Respirology</i> , 2010, 15, 365-376.	1.3	3
171	Does the current stepwise approach to asthma pharmacotherapy encourage overâ€treatment?. <i>Respirology</i> , 2010, 15, 596-602.	1.3	11
172	The Beliefs And Behaviours Which Predict Objectively Measured Adherence To Inhaled Corticosteroids In Asthma. , 2010, , .		1
173	Measuring asthma control: a comparison of three classification systems. <i>European Respiratory Journal</i> , 2010, 36, 269-276.	3.1	80
174	Rhinovirus-Induced Exacerbations of Asthma. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2010, 43, 227-233.	1.4	32
175	Overall asthma control: The relationship between current control and future risk. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 600-608.e6.	1.5	219
176	Obesity and asthma control in an urban population. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 769-770.	1.5	6
177	Down-titration from high-dose combination therapy in asthma: Removal of long-acting Î²2-agonist. <i>Respiratory Medicine</i> , 2010, 104, 1110-1120.	1.3	58
178	Session 4A: Community Pharmacy. <i>International Journal of Pharmacy Practice</i> , 2010, 18, 40-43.	0.3	28
179	Metered-Dose Inhaler Technique: The Effect of Two Educational Interventions Delivered in Community Pharmacy Over Time. <i>Journal of Asthma</i> , 2010, 47, 251-256.	0.9	164
180	Increasing the dose of inhaled corticosteroid when asthma deteriorates â€“ does it prevent severe exacerbations?. <i>Polish Archives of Internal Medicine</i> , 2010, 120, 64-67.	0.3	1

#	ARTICLE	IF	CITATIONS
181	Cost is a major barrier to the use of inhaled corticosteroids for obstructive lung disease. Medical Journal of Australia, 2009, 191, 319-323.	0.8	16
182	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 59-99.	2.5	1,591
183	Impact factor and its role in academic promotion. European Respiratory Journal, 2009, 34, 1499-1500.	3.1	8
184	Characterizing asthma phenotypes: Predictors and outcomes at the extremes of asthma severity. Respiriology, 2009, 14, 778-780.	1.3	5
185	Long-Term Maintenance of Pharmacists' Inhaler Technique Demonstration Skills. American Journal of Pharmaceutical Education, 2009, 73, 32.	0.7	76
186	Evaluation of a novel educational strategy, including inhaler-based reminder labels, to improve asthma inhaler technique. Patient Education and Counseling, 2008, 72, 26-33.	1.0	142
187	Pharmacist interventions in asthma. European Respiratory Journal, 2008, 32, 812-812.	3.1	5
188	A new perspective on concepts of asthma severity and control. European Respiratory Journal, 2008, 32, 545-554.	3.1	372
189	Does continuous use of inhaled corticosteroids improve outcomes in mild asthma? A double-blind randomised controlled trial. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2008, 17, 39-45.	2.5	21
190	Measuring peak flow enhances adherence to monitoring in asthma. Thorax, 2007, 62, 741-742.	2.7	9
191	The benefit of experience: patient perception of asthma self-management. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2007, 16, 68-70.	2.5	5
192	Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. Journal of Allergy and Clinical Immunology, 2007, 119, 1537-1538.	1.5	169
193	Short-term variability of airway caliber "a marker of asthma?. Journal of Applied Physiology, 2007, 103, 296-304.	1.2	31
194	Patient preferences for managing asthma: results from a discrete choice experiment. Health Economics (United Kingdom), 2007, 16, 703-717.	0.8	78
195	Using discrete choice experiments to investigate subject preferences for preventive asthma medication. Respiriology, 2007, 12, 127-136.	1.3	58
196	"Exasperations" of asthma: a qualitative study of patient language about worsening asthma. Medical Journal of Australia, 2006, 184, 451-454.	0.8	26
197	Peak flow monitoring in clinical practice and clinical asthma trials. Current Opinion in Pulmonary Medicine, 2006, 12, 75-81.	1.2	29
198	Complementary and alternative medicine use in asthma: Who is using what?. Respiriology, 2006, 11, 373-387.	1.3	138

#	ARTICLE	IF	CITATIONS
199	Pharmacological strategies for self-management of asthma exacerbations. <i>European Respiratory Journal</i> , 2006, 28, 182-199.	3.1	56
200	Double blind randomised controlled trial of two different breathing techniques in the management of asthma. <i>Thorax</i> , 2006, 61, 651-656.	2.7	73
201	The reduction of rhinitis symptoms by nasal filters during natural exposure to ragweed and grass pollen. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 529-532.	2.7	51
202	Traditional and patient-centred outcomes with three classes of asthma medication. <i>European Respiratory Journal</i> , 2005, 26, 36-44.	3.1	66
203	The need for standardisation of peak flow charts. <i>Thorax</i> , 2005, 60, 164-167.	2.7	19
204	Questionnaire Responses That Predict Airway Response to Hypertonic Saline. <i>Respiration</i> , 2005, 72, 52-60.	1.2	16
205	Counseling about turbuhaler technique: needs assessment and effective strategies for community pharmacists. <i>Respiratory Care</i> , 2005, 50, 617-23.	0.8	70
206	Goals of asthma treatment: how high should we go?. <i>European Respiratory Journal</i> , 2004, 24, 715-717.	3.1	16
207	When can personal best peak flow be determined for asthma action plans?. <i>Thorax</i> , 2004, 59, 922-924.	2.7	34
208	Lack of Awareness of Need to Clean CFC-Free Metered-Dose Inhalers. <i>Journal of Asthma</i> , 2004, 41, 367-373.	0.9	5
209	Effect of Mouthpiece Washing on Aerosol Performance of CFC-Free Ventolin [®] . <i>Journal of Asthma</i> , 2004, 41, 721-727.	0.9	6
210	Effect of Budesonide on the Perception of Induced Airway Narrowing in Subjects with Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 15-21.	2.5	47
211	Analysis of adherence to peak flow monitoring when recording of data is electronic. <i>BMJ: British Medical Journal</i> , 2002, 324, 146-147.	2.4	47
212	Sodium cromoglycate in asthma. <i>Thorax</i> , 2001, 56, 896-896.	2.7	1
213	Optimal asthma control, starting with high doses of inhaled budesonide. <i>European Respiratory Journal</i> , 2000, 16, 226.	3.1	150
214	Diurnal variability--time to change asthma guidelines?. <i>BMJ: British Medical Journal</i> , 1999, 319, 45-47.	2.4	41
215	Differences between asthma exacerbations and poor asthma control. <i>Lancet, The</i> , 1999, 353, 364-369.	6.3	245
216	Pitfalls in processing home electronic spirometric data in asthma. <i>European Respiratory Journal</i> , 1998, 12, 853-858.	3.1	34

#	ARTICLE	IF	CITATIONS
217	Assessment of Airway Responsiveness as a Guide to Diagnosis, Prognosis, and Therapy in Asthma. Allergy and Asthma Proceedings, 1995, 16, 23-26.	1.0	2
218	Human mesothelioma cells and asbestos-exposed mesothelial cells are selectively resistant to amosite toxicity: a possible mechanism for tumor promotion by asbestos. Carcinogenesis, 1992, 13, 1359-1363.	1.3	8
219	Dose-dependent pharmacokinetics with single daily dose slow release theophylline in patients with chronic lung disease.. British Journal of Clinical Pharmacology, 1982, 13, 241-243.	1.1	9
220	BRONCHODILATOR ACTION OF PRAZOSIN. Lancet, The, 1981, 317, 225.	6.3	12